Zannettino ACW - Search Results

1

Cutting edge genomics reveal new insights into tumour development, disease progression and therapeutic impacts in multiple myeloma.

Dutta AK, Hewett DR, Fink JL, Grady JP, Zannettino ACW. Dutta AK, et al. Among authors: zannettino acw. Br J Haematol. 2017 Jul;178(2):196-208. doi: 10.1111/bjh.14649. Epub 2017 May 3. Br J Haematol. 2017. PMID: 28466550 Free article. Review.

2

Circulating N-cadherin levels are a negative prognostic indicator in patients with multiple myeloma.

Vandyke K, Chow AW, Williams SA, To LB, Zannettino AC. Vandyke K, et al. Br J Haematol. 2013 May;161(4):499-507. doi: 10.1111/bjh.12280. Epub 2013 Feb 26. Br J Haematol. 2013. PMID: 23438504 Free article.

3

SAMSN1 is a tumor suppressor gene in multiple myeloma.

Noll JE, Hewett DR, Williams SA, Vandyke K, Kok C, To LB, Zannettino AC. Noll JE, et al. Neoplasia. 2014 Jul;16(7):572-85. doi: 10.1016/j.neo.2014.07.002. Neoplasia. 2014. PMID: 25117979 Free PMC article.

4

The effect of the dual PI3K and mTOR inhibitor BEZ235 on tumour growth and osteolytic bone disease in multiple myeloma.

Gan ZY, Fitter S, Vandyke K, To LB, Zannettino AC, Martin SK. Gan ZY, et al. Eur J Haematol. 2015 Apr;94(4):343-54. doi: 10.1111/ejh.12436. Epub 2014 Sep 17. Eur J Haematol. 2015. PMID: 25179233

5

Brief report: the differential roles of mTORC1 and mTORC2 in mesenchymal stem cell differentiation.

Martin SK, Fitter S, Dutta AK, Matthews MP, Walkley CR, Hall MN, Ruegg MA, Gronthos S, Zannettino AC. Martin SK, et al. Stem Cells. 2015 Apr;33(4):1359-65. doi: 10.1002/stem.1931. Stem Cells. 2015. PMID: 25537496

6

The effect of the PI3K inhibitor BKM120 on tumour growth and osteolytic bone disease in multiple myeloma.

Martin SK, Gan ZY, Fitter S, To LB, Zannettino AC. Martin SK, et al. Leuk Res. 2015 Mar;39(3):380-7. doi: 10.1016/j.leukres.2014.12.015. Epub 2015 Jan 7. Leuk Res. 2015. PMID: 25624048

7

Tetraspanin 7 (TSPAN7) expression is upregulated in multiple myeloma patients and inhibits myeloma tumour development in vivo.

Cheong CM, Chow AW, Fitter S, Hewett DR, Martin SK, Williams SA, To LB, Zannettino AC, Vandyke K. Cheong CM, et al. Exp Cell Res. 2015 Mar 1;332(1):24-38. doi: 10.1016/j.yexcr.2015.01.006. Epub 2015 Jan 28. Exp Cell Res. 2015. PMID: 25637218

8

Therapeutic targeting of N-cadherin is an effective treatment for multiple myeloma.

Mrozik KM, Cheong CM, Hewett D, Chow AW, Blaschuk OW, Zannettino AC, Vandyke K. Mrozik KM, et al. Br J Haematol. 2015 Nov;171(3):387-99. doi: 10.1111/bjh.13596. Epub 2015 Jul 20. Br J Haematol. 2015. PMID: 26194766 Free article.

9

PTTG1 expression is associated with hyperproliferative disease and poor prognosis in multiple myeloma.

Noll JE, Vandyke K, Hewett DR, Mrozik KM, Bala RJ, Williams SA, Kok CH, Zannettino AC. Noll JE, et al. J Hematol Oncol. 2015 Oct 6;8:106. doi: 10.1186/s13045-015-0209-2. J Hematol Oncol. 2015. PMID: 26445238 Free PMC article.

10

The cationic small molecule GW4869 is cytotoxic to high phosphatidylserine-expressing myeloma cells.

Vuckovic S, Vandyke K, Rickards DA, McCauley Winter P, Brown SHJ, Mitchell TW, Liu J, Lu J, Askenase PW, Yuriev E, Capuano B, Ramsland PA, Hill GR, Zannettino ACW, Hutchinson AT. Vuckovic S, et al. Among authors: zannettino acw. Br J Haematol. 2017 May;177(3):423-440. doi: 10.1111/bjh.14561. Epub 2017 Feb 17. Br J Haematol. 2017. PMID: 28211573 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

215 results

Search Page